Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients
暂无分享,去创建一个
Tim Friede | Raees Ahmed | Oliver Gross | T. Friede | O. Gross | Reinhard Hilgers | Anke Görlitz | Karsten Gavénis | Ulrike Dürr | R. Hilgers | A. Goerlitz | Raees Ahmed | Karsten Gavénis | Ulrike Dürr
[1] F. Schaefer,et al. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. , 2004, Kidney international.
[2] T. Seeman,et al. Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases. , 2004, American journal of hypertension.
[3] E. Schulze-Lohoff,et al. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. , 2003, Kidney international.
[4] R. Kalluri,et al. Choosing a mouse model to study the molecular pathobiology of Alport glomerulonephritis. , 2007, Kidney international.
[5] O. Gross,et al. Treatment of Alport syndrome: beyond animal models. , 2009, Kidney international.
[6] M. Van Dyck,et al. Enalapril in children with Alport syndrome , 2004, Pediatric Nephrology.
[7] O. Gross,et al. Von der Molekulargenetik des Alport-Syndroms zu Prinzipien der Organprotektion bei chronischen Nierenerkrankungen , 2005, Medizinische Klinik.
[8] O. Gross,et al. [From the molecular genetics of Alport's syndrome to principles of organo-protection in chronic renal diseases]. , 2005, Medizinische Klinik.
[9] K. Tryggvason,et al. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. , 2003, The New England journal of medicine.
[10] J C Lindsey,et al. Tutorial in biostatistics methods for interval-censored data. , 1998, Statistics in medicine.
[11] T. Friede,et al. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. , 2012, Kidney international.